Of particular interest, several trials have focused on LRRK2-derived EVs (NCT01860118, NCT04603326, NCT03775447) as potential PD biomarkers, which are known to regulate vesicle trafficking and cytoskeletal dynamics associated with PC and TNTs. Here, LRRK2 is linked to Parkinson disease.